Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1584 - Prognostic significance of serum Beta 2 Microglobulin in Non Hodgkin Lymphoma (33P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Garima Gupta

Citation

Annals of Oncology (2017) 28 (suppl_10): x7-x15. 10.1093/annonc/mdx653

Authors

G. Gupta1, V.S. Ghalaut2, V. Lokanathan2, P. Sharma1

Author affiliations

  • 1 Biochemistry, All India Institute Of Medical Sciences(AIIMS), 342005 - Jodhpur/IN
  • 2 Biochemistry, PGIMS, 124001 - Rohtak/IN
More

Resources

Abstract 1584

Background

Lymphoma has been described as the proliferation of lymphoid cells, arising as discrete tissue masses. 85% of all the malignant lymphoma are found to be NHL. Beta 2 microglobulin (B2M) is a small (11,800-dalton) protein, present in nearly all nucleated cells and biological fluids, including serum, urine, and synovial fluid. It forms the light chain subunit of the MHC class I antigen. The objective of this study was to determine the role of serum levels of B2M in the prognosis of patients with NHL so as to strengthen its potential role as a convenient non-invasive biomarker.

Methods

Fifty diagnosed cases of NHL and fifty age and sex matched healthy controls were taken. Serum levels of B2M were estimated in newly diagnosed patients before initiating treatment and in controls by ELISA. The patients were treated with CHOP Regimen (cyclophosphamide, hydroxydaunomycin, oncovin, and prednisolone). Serum B2M was estimated again upon completion of six chemotherapeutic cycles.

Results

Serum B2M levels significantly higher (P< 0.01) in NHL patients (5.66±2.14 μg/ml) than in controls (1.47± 0.60 μg/ml); they were also higher in patients in advanced stages (stage III and IV) (8.30±0.096 μg/ml) than those in early (stage I and stage II) (3.4804±.085μg/ml) (P

Conclusions

The data obtained shows that serum B2M test can be an important prognostic tool for assessment of treatment response in NHL patients, as serum levels were significantly higher in the pretreatment group than post treatment group; they also declined significantly only in patients achieving remission. Further, as B2M levels were also correlated with advanced stage, they may reflect the total amount or turnover of malignant cells in the body. Therefore, repeated determinations of serum B2M in these patients might be useful as an estimate of the residual malignant cell mass after therapy. Thus, whereas elevated B2M levels indicated high turnover of lymphoma cells, low levels after chemotherapy might indicate the achievement of remission in NHL cases.

Clinical trial identification

Legal entity responsible for the study

PGIMS Rohtak

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings